Marksans Pharma soars after its arm secures marketing authorization for three products
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Marksans Pharma is currently trading at Rs. 223.30, up by 2.40 points or 1.09% from its previous closing of Rs. 220.90 on the BSE.
The scrip opened at Rs. 220.05 and has touched a high and low of Rs. 224.95 and Rs. 218.45 respectively. So far 180885 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 224.95 on 21-Aug-2024 and a 52 week low of Rs. 93.85 on 18-Sep-2023.
Last one week high and low of the scrip stood at Rs. 224.95 and Rs. 207.35 respectively. The current market cap of the company is Rs. 10182.59 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 22.34% and 33.78% respectively.
Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization from UKMHRA for the three products. These products are Fluoxetine 10mg Capsules, Fluoxetine 30mg Capsules and Fluoxetine 60mg Capsules.
Earlier, the USFDA had issued an Establishment Inspection Report (EIR) for the manufacturing facility of Marksans Pharma located at Verna Industrial estate, Verna, Goa, India.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
